Intratumoral delivery of beta-lapachone via polymer implants for prostate cancer therapy - Wikidata - wikimedia - TriplyDB

Intratumoral delivery of beta-lapachone via polymer implants for prostate cancer therapy

Intratumoral delivery of beta-lapachone via polymer implants for prostate cancer therapy

http://www.wikidata.org/entity/Q33753357

about

Implications of NQO1 in cancer therapy Modulating endogenous NQO1 levels identifies key regulatory mechanisms of action of β-lapachone for pancreatic cancer therapy.Polymeric implants for the delivery of green tea polyphenols.Tumor-selective, futile redox cycle-induced bystander effects elicited by NQO1 bioactivatable radiosensitizing drugs in triple-negative breast cancers.Beta-lapachone micellar nanotherapeutics for non-small cell lung cancer therapy.Endoplasmic reticulum stress-induced JNK activation is a critical event leading to mitochondria-mediated cell death caused by β-lapachone treatment.New potential for enhancing concomitant chemoradiotherapy with FDA approved concentrations of cisplatin via the photoelectric effect.PRX1 knockdown potentiates vitamin K3 toxicity in cancer cells: a potential new therapeutic perspective for an old drug.Review of poly (ADP-ribose) polymerase (PARP) mechanisms of action and rationale for targeting in cancer and other diseases.Targeted radiotherapy with gold nanoparticles: current status and future perspectives.Injectable SN-38-loaded Polymeric Depots for Cancer Chemotherapy of Glioblastoma Multiforme.β-Lapachone Induces NAD(P)H:Quinone Oxidoreductase-1- and Oxidative Stress-Dependent Heat Shock Protein 90 Cleavage and Inhibits Tumor Growth and Angiogenesis.Preclinical Pharmacokinetic Evaluation of β-Lapachone: Characteristics of Oral Bioavailability and First-Pass Metabolism in Rats.Dimeric naphthoquinones, a novel class of compounds with prostate cancer cytotoxicity.Hyperthermia enhances the effect of β-lapachone to cause γH2AX formations and cell death in human osteosarcoma cells.Heat shock increases expression of NAD(P)H:quinone oxidoreductase (NQO1), mediator of beta-lapachone cytotoxicity, by increasing NQO1 gene activity and via Hsp70-mediated stabilisation of NQO1 protein.Prostate cancer radiosensitization through poly(ADP-Ribose) polymerase-1 hyperactivation.Enhanced antitumor efficacy of poly(D,L-lactide-co-glycolide)-based methotrexate-loaded implants on sarcoma 180 tumor-bearing mice.Lysosome-oriented, dual-stage pH-responsive polymeric micelles for β-Lapachone delivery.Using a novel NQO1 bioactivatable drug, beta-lapachone (ARQ761), to enhance chemotherapeutic effects by metabolic modulation in pancreatic cancer.Characterization and antitumor efficacy of poly(L-lactid acid)-based etoposide-loaded implants.

P2860

Q26783702-BEF2F144-864E-40A5-85C3-D040519ED3A0 Q27346846-E877B77B-9BF9-4083-862F-9AF22B3E6BFD Q33564764-D9563915-4084-4DB2-AD2E-F9F4865D5474 Q33767952-67FD696F-1D94-4380-AD25-6C8EAB6BB2F7 Q33862927-3ED0BE71-056A-4B84-B9B2-55FEF3B77220 Q33955000-359B4B30-42CD-4EC1-A994-8AE6C2CEAD8D Q35821336-82F33B35-C0A7-48CE-A8A5-AAF005B07194 Q36393755-6EAE2046-C3A0-4A6D-B8F8-2D57AEFFFB31 Q38191981-9B93DEE3-1AB8-4586-BCA8-4940FC6F0BEE Q38224610-B555B7DC-2B47-4198-A93C-6A9AC61DA5AF Q38734048-2F290FE1-FC22-4C76-9143-016A1FC7BC66 Q38780512-1B27155B-790D-46F8-8D24-FA5DDDFDEF7E Q39004214-D0BF226B-F86C-476C-B349-04BCC5D2C7F4 Q39617420-4A738557-D60A-459B-B5BC-EE8060D3C68C Q39633123-381E6FD2-2C0D-4990-8DC5-A08A62ECD9BC Q39816199-34F8783B-3BC9-4C0A-8EDE-BF4E9194FE17 Q42409402-01C18D76-E955-486D-BE2C-2DC0A8D55A31 Q44723040-E83390B9-104D-4FAE-AED2-294F59E56F35 Q46086889-859F53C0-43F3-4F33-92D0-B68F2125F24E Q48356862-187B7D0A-B1B8-4E64-BF7D-EEA20C921005 Q50887645-9BAF7DAF-92AF-4D15-A1E7-4742A504D006

P2860

Intratumoral delivery of beta-lapachone via polymer implants for prostate cancer therapy

http://www.wikidata.org/entity/Q33753357

description

2009 nî lūn-bûn

@nan

2009 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Intratumoral delivery of beta-lapachone via polymer implants for prostate cancer therapy

@ast

Intratumoral delivery of beta-lapachone via polymer implants for prostate cancer therapy

@en

type

label

Intratumoral delivery of beta-lapachone via polymer implants for prostate cancer therapy

@ast

Intratumoral delivery of beta-lapachone via polymer implants for prostate cancer therapy

@en

prefLabel

Intratumoral delivery of beta-lapachone via polymer implants for prostate cancer therapy

@ast

Intratumoral delivery of beta-lapachone via polymer implants for prostate cancer therapy

@en

P1433

Q33753357-9F7F6AEE-3932-4810-BB96-89B5F77C46E7

P1476

Q33753357-3636F450-7ADF-401E-86B3-A66ECFADFDFC

P2093

Q33753357-383B18C4-DAAC-426E-B817-065935D8CC2D

Q33753357-3E5A675D-B21D-4766-9C99-E4B6FF428D24

Q33753357-5FAE949C-347F-4284-86BA-5A519608E021

Q33753357-7A464D19-A520-4468-A1F1-74ADC7CC2E24

Q33753357-9908339B-C251-4FC7-BC6A-7456B699E00B

Q33753357-B3F25403-E1D2-419B-A429-A01D2CF9109C

Q33753357-BAE0CA07-AC4C-4537-A33D-FC4C55100CAC

Q33753357-E05F7670-CC66-4575-B6DF-1EADC660DE0F

P2860

Q33753357-05F527D3-6BF9-476E-852E-D151DA3E7395

Q33753357-0C07E847-863B-4646-A154-C42D1C918830

Q33753357-0FDD844A-C5A5-481F-A976-28962DD2924F

Q33753357-138DFB9E-2BF3-407D-BB08-E1BB6DF2AE80

Q33753357-14BE35A6-33B3-4249-8118-3EB31D577315

Q33753357-14F34BF9-DF43-4DD3-93E8-E757322808E7

Q33753357-21889012-9EBA-4F3C-8B41-ED47335B0C23

Q33753357-2977F6A4-CAA6-43E3-9B5A-6B450D7D89A0

Q33753357-304C2325-8B58-46F2-910D-599F038B7B10

Q33753357-30C1ABB1-BED9-4002-B22F-A562B372A1A6

P304

Q33753357-C0399503-574D-4CE3-92BA-A5CEA4F03A83

P31

Q33753357-89EC1D33-4BAB-4348-8DB1-2652A55198EB

P356

Q33753357-74F038AE-41C8-4CAE-A78E-0BC4ACC7830C

P407

Q33753357-EC80E986-D2CD-48B0-BB9C-80A00BC1DC46

P433

Q33753357-0D6DC051-64B0-49EA-BB4B-4BFBB74081C9

P478

Q33753357-341DADD5-63D1-4D55-9405-5EFE2A91750D

P50

Q33753357-78c87e98-493c-4755-75d5-b8a6bae070f3

P577

Q33753357-8B3B0B0E-FA5A-4BBA-A0B4-024CA72B37D3

P5875

Q33753357-17F9ED2B-EE34-4C86-8D5E-0DD2FDA3F9B6

P698

Q33753357-4B165F25-EE06-4F5D-A116-BD615CF47746

P932

Q33753357-2C01B276-944F-4ABA-80E8-137BCDBFC391

P356

1078-0432.CCR-08-1691

P1433

Clinical Cancer Research

P1476

Intratumoral delivery of beta-lapachone via polymer implants for prostate cancer therapy

@en

P2093

David A Boothman

http://www.w3.org/2001/XMLSchema#string

Erik A Bey

http://www.w3.org/2001/XMLSchema#string

Jinming Gao

http://www.w3.org/2001/XMLSchema#string

Shook-Fong Chin

http://www.w3.org/2001/XMLSchema#string

Wareef Kabbani

http://www.w3.org/2001/XMLSchema#string

William G Bornmann

http://www.w3.org/2001/XMLSchema#string

Xian-Jin Xie

http://www.w3.org/2001/XMLSchema#string

Ying Dong

http://www.w3.org/2001/XMLSchema#string

P2860

Small-scale systems for in vivo drug delivery

Cancer statistics, 2007

Development of beta-lapachone prodrugs for therapy against human cancer cells with elevated NAD(P)H:quinone oxidoreductase 1 levels.

Gliadel wafers in the treatment of malignant glioma: a systematic review.

Signaling for the caspases: their role in prostate cell apoptosis.

Docetaxel in prostate cancer.

Mutations within the tumour suppressor gene p53 are not confined to a late event in prostate cancer progression. a review of the evidence.

Pharmacokinetics of the carmustine implant.

Current strategies in the management of hormone refractory prostate cancer.

Docetaxel (taxotere) in the treatment of prostate cancer.

P304

131-139

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-08-1691

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P50

P577

2009-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23715242

http://www.w3.org/2001/XMLSchema#string

P698

19118040

http://www.w3.org/2001/XMLSchema#string

P932

2845536

http://www.w3.org/2001/XMLSchema#string